Results 11 to 20 of about 34,322 (240)

Adalimumab in the treatment of cardiac sarcoidosis: Single center case series and narrative literature review

Respiratory Medicine Case Reports, 2022
Background: Tumor necrosis factor (TNF) inhibitors have been used in the treatment of cardiac sarcoidosis, infliximab being the most commonly used.
Jaleel Jerry G. Sweis, Nabil William G. Sweis, Christian Ascoli, Benjamin Levin, Boaz Avitall, Israel Rubinstein, George Kondos, Daniel A. Culver, Marc Judson, Robert Baughman, Dawood Darbar, Wonder Drake, Shiva Shahrara, Leslie T. Cooper, Jr., Nadera J. Sweiss   +14 more
doaj   +1 more source

Long-Term Dose Optimization of Adalimumab via Dose Spacing in Patients with Psoriasis

Bioengineering, 2022
Dose spacing (DS) can be useful for optimizing treatment with biologics in psoriasis patients. However, interval prolongation might increase the production of anti-drug antibodies (ADA) and, therefore, reduce the drug’s effectiveness.
Michael Benzaquen, Mohammad Munshi, Simon Bossart, Laurence Feldmeyer, Vladimir Emelianov, Nikhil Yawalkar, Simone Cazzaniga, Kristine Heidemeyer   +7 more
doaj   +1 more source

Methotrexate effect on immunogenicity and long-term maintenance of adalimumab in axial spondyloarthritis: a multicentric randomised trial

RMD Open, 2020
Objectives Anti-drug antibodies (ADA) are responsible for decreased adalimumab efficacy in axial spondyloarthritis (SpA). We aimed to evaluate the ability of methotrexate (MTX) to decrease adalimumab immunisation.Methods A total of 110 patients eligible ...
Grégoire Cormier, Benoit Le Goff, Emmanuelle Dernis, Philippe Goupille, Aleth Perdriger, Theo Rispens, David Ternant, Gilles Paintaud, Emilie Ducourau, Marine Samain, Fabienne Le Guilchard, Lucia Andras, Eric Lespessailles, Thomas Armingeat, Valérie Devauchelle-Pensec, Elisabeth Gervais, Annick de Vries, Eric Piver, Céline Desvignes, Hervé Watier, Denis Mulleman   +20 more
doaj   +1 more source

Efficacy and safety of cyclosporin, adalimumab and secukinumab in the treatment of nail psoriasis

Pifu-xingbing zhenliaoxue zazhi, 2023
Objective To assess the clinical efficacy and safety of cyclosporin, adalimumab and secukinumab in the treatment of nail psoriasis. Methods Ninety-one patients with nail psoriasis from our hospital were randomly divided into cyclosporin group (30 cases),
Zhanhan TANG, Sushan LI, Sha LV, Zhao HUANG, Zhe LIU, Fuqiu LI   +5 more
doaj   +1 more source

Adalimumab Dose-Escalation Therapy Is Effective in Refractory Crohn’s Disease Patients with Loss of Response to Adalimumab, Especially in Cases without Previous Infliximab Treatment

Case Reports in Gastroenterology, 2019
Background/Aims: Adalimumab dose escalation is one of the most important options in refractory Crohn’s disease patients with loss of response to adalimumab. The goal of this study was to evaluate the effectiveness of adalimumab dose escalation in Crohn’s
Taketo Suzuki, Tsutomu Mizoshita, Tomoya Sugiyama, Yoshikazu Hirata, Yoshihide Kimura, Yuka Suzuki, Tomonori Yamada, Hironobu Tsukamoto, Takashi Mizushima, Naomi Sugimura, Takahito Katano, Satoshi Tanida, Hiromi Kataoka, Makoto Sasaki   +13 more
doaj   +1 more source

Comparision of the efficacy and safety between Secukinumab and Adalimumab in the treatment of the moderate to severe plaque psoriasis

Pifu-xingbing zhenliaoxue zazhi, 2023
Objective To evaluate the efficacy and safety of Secukinumab versus Adalimumab in the treatment of the moderate to severe plaque psoriasis. Methods A total of 90 patients with moderate to severe psoriasis were randomly divided into three groups ...
Dandan HU, Peimiao ZHANG
doaj   +1 more source

Early Adalimumab and Anti‐Adalimumab Antibody Levels for Prediction of Primary Nonresponse in Ankylosing Spondylitis Patients

Clinical and Translational Science, 2020
This study aimed at exploring the concentration‐effect relationship of adalimumab and early adalimumab and anti‐adalimumab antibody (AAA) levels in predicting primary nonresponse in a real‐world pilot cohort of patients with ankylosing spondylitis ...
Xiaoliang Ding, Ruifang Zhu, Jian Wu, Ling Xue, Meihua Gu, Liyan Miao   +5 more
doaj   +1 more source

Protective Effect of Adalimumab on Diabetic Nephropathy by Regulating TNF-α Signal Pathway

Iranian Journal of Public Health, 2021
Background: To evaluate the inhibitory effect of adalimumab on diabetic nephropathyDN) through animal models. Methods: We carried out the study in Weifang People’s Hospital, Weifang 261041, China in December 2020.
Zhiying Ding, Hongxia Jiang, Yongsong Fan, Guiqin Sun   +3 more
doaj   +1 more source

Outcome of adalimumab monotherapy in paediatric non-infectious uveitis

Pediatric Rheumatology Online Journal, 2023
Background Adalimumab in combination with other disease-modifying antirheumatic drugs (DMARD) such as methotrexate has a proven efficacy in the management of paediatric non-infectious uveitis.
DA Al-Julandani, NK Bagri, N Tsang, S Clarke, A Upadhyay, C Guly, AV Ramanan   +6 more
doaj   +1 more source

Adalimumab in Psoriatic Arthritis

The Journal of Rheumatology Supplement, 2012
Open prospective studies and randomized controlled trials (RCT) have shown the short-term efficacy of adalimumab (ADA) in psoriatic arthritis (PsA) and psoriasis. ADA effectively treated all varied musculoskeletal manifestations characteristic of PsA, including peripheral arthritis, spinal disease, enthesitis, and dactylitis.
SALVARANI, CARLO, Pipitone, Nicolò, Catanoso, Mariagrazia, Chiarolanza, Ilaria, Boiardi, Luigi, Caruso, Andrea, Pazzola, Giulia, Macchioni, Pierluigi, Di Lernia, Vito, Albertini, Giuseppe   +9 more
openaire   +4 more sources